about
Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells.Dendritic cells and immunotherapy for malignant disease.To find the road traveled to tumor immunity: the trafficking itineraries of molecular chaperones in antigen-presenting cells.The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.Against the self: dendritic cells versus cancer.Neutrophils sustain pathogenic CD8+ T cell responses in the heart.Challenges facing adjuvants for cancer immunotherapy.Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells.Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections.Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens.A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.The cross-priming pathway: a portrait of an intricate immune system.Requirement of B cells for generating CD4+ T cell memory.The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cellsImmune recognition and rejection of allogeneic skin grafts.Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy.The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro.Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming.Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response.IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.The Use of Anti-CD40 mAb in Cancer.The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes
P2860
Q33835246-731BC31F-8285-4484-9A9B-E561E71E5ABFQ34145128-741AB1C4-7D90-413F-B173-5E597D1E7678Q34216506-83288C94-EE1B-4817-B7C1-468FA16A3E86Q34384100-8A94299B-837F-409C-9E20-3A47298E9DC3Q34472265-19EB8885-9A4F-4DB8-8999-E7FA9D538599Q35144042-A7B1CA36-E81B-4D99-9396-54794CE02973Q35219334-D414C392-CEB5-4795-AAF4-2D47E1C15C01Q35843331-899024CE-B2E2-4539-B764-9D6413FB72AEQ35953773-DDC38441-3244-46A0-A497-D522E9478A4BQ36369790-72144F8C-39A2-42EB-8B6A-D442615CDE18Q36371363-EC3E0854-5CE5-4CBF-8200-F9E2790BF9E4Q36376041-A251696D-D2DE-4BF6-AE16-53AF838351DFQ36711264-5DEEEDDB-7C3A-4582-A0FA-88CAE3C5DAC5Q36770431-A14A5850-09AA-4DF2-87E4-10F29AF24667Q37135496-3A95BA87-E3A7-4C7D-947E-AC0579D1278EQ37327058-A3661AD5-A545-4000-BCE5-A493781F23D9Q37888686-A62CD50D-A894-4257-99CE-B09F98A8EC61Q38068470-6D60E29D-8872-4524-AD09-EBDEAFAEC9C2Q38990679-B0C487E5-FCE7-4F77-8CFE-ECF42EA95D87Q40423168-BB0C75CE-48D0-4D5C-A5AE-55B3571A4665Q40795464-0B331C38-03CA-4C81-B449-103AD08241FBQ42972789-AB14E534-381A-4FC7-ACC9-0018EB081368Q44940165-893C4EF3-DA4B-4E36-9E80-86E6E7D401DCQ45642718-48AF49C7-49AA-4218-8213-CDBD11D6AEBEQ45871399-3F821301-CE2A-4FD2-8677-D5CC7F092142Q53321210-1A128708-7357-49D4-A6D4-948885DEF85DQ59136982-16EAB62E-4ED8-43EB-9DAA-5F5E05C6CBB2
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cytotoxic T lymphocyte activation by cross-priming.
@ast
Cytotoxic T lymphocyte activation by cross-priming.
@en
type
label
Cytotoxic T lymphocyte activation by cross-priming.
@ast
Cytotoxic T lymphocyte activation by cross-priming.
@en
prefLabel
Cytotoxic T lymphocyte activation by cross-priming.
@ast
Cytotoxic T lymphocyte activation by cross-priming.
@en
P1476
Cytotoxic T lymphocyte activation by cross-priming.
@en
P2093
P304
P356
10.1016/S0952-7915(99)80050-8
P577
1999-06-01T00:00:00Z